Infinity Pharmaceuticals Analyst Ratings
Infinity Pharmaceuticals Analyst Ratings
While ratings are subjective and will change, the latest Infinity Pharmaceuticals (INFI) rating was a downgraded with a price target of $3.00 to $1.50. The current price Infinity Pharmaceuticals (INFI) is trading at is $0.79, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/16/2022 | 90.36% | B. Riley Securities | $3 → $1.5 | Downgrades | Buy → Neutral |
| 05/23/2022 | 280.71% | Piper Sandler | $4 → $3 | Maintains | Overweight |
| 03/31/2022 | 407.61% | Truist Securities | $12 → $4 | Maintains | Buy |
| 03/30/2022 | 407.61% | Piper Sandler | $8 → $4 | Maintains | Overweight |
| 10/18/2021 | 1042.13% | HC Wainwright & Co. | → $9 | Initiates Coverage On | → Buy |
| 08/02/2021 | 661.42% | JP Morgan | → $6 | Upgrades | Neutral → Overweight |
| 07/28/2021 | 1676.65% | Wells Fargo | $4 → $14 | Upgrades | Equal-Weight → Overweight |
| 03/18/2021 | 1422.84% | Truist Securities | → $12 | Initiates Coverage On | → Buy |
| 03/17/2021 | 407.61% | Wells Fargo | $2 → $4 | Maintains | Equal-Weight |
| 02/18/2021 | 788.32% | Piper Sandler | → $7 | Initiates Coverage On | → Overweight |
| 02/05/2021 | — | JP Morgan | Upgrades | Underweight → Neutral | |
| 05/18/2020 | 217.26% | B. Riley Securities | $3.5 → $2.5 | Maintains | Buy |
| 05/12/2020 | 26.9% | Wells Fargo | $1.5 → $1 | Maintains | Equal-Weight |
| 03/04/2020 | 90.36% | Wells Fargo | $2.5 → $1.5 | Maintains | Equal-Weight |
| 11/18/2019 | 344.16% | B. Riley Securities | → $3.5 | Reinstates | → Buy |
| 06/27/2019 | 280.71% | Oppenheimer | → $3 | Initiates Coverage On | → Outperform |
| 01/04/2019 | 280.71% | B. Riley Securities | → $3 | Initiates Coverage On | → Buy |
| 11/12/2018 | — | Wells Fargo | Downgrades | Outperform → Market Perform | |
| 11/12/2018 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 05/31/2018 | 407.61% | Seaport Global | → $4 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 11/16/2022 | 90.36% | B.萊利證券 | $3 → $1.5 | 評級下調 | 購買→中性 |
| 05/23/2022 | 280.71% | 派珀·桑德勒 | $4 → $3 | 維護 | 超重 |
| 03/31/2022 | 407.61% | Truist證券 | $12 → $4 | 維護 | 買 |
| 03/30/2022 | 407.61% | 派珀·桑德勒 | $8 → $4 | 維護 | 超重 |
| 10/18/2021 | 1042.13% | HC Wainwright公司 | → $9 | 開始承保 | →購買 |
| 08/02/2021 | 661.42% | 摩根大通 | → $6 | 升級 | 中性→超重 |
| 07/28/2021 | 1676.65% | 富國銀行 | $4 → $14 | 升級 | 等重→超重 |
| 03/18/2021 | 1422.84% | Truist證券 | → $12 | 開始承保 | →購買 |
| 03/17/2021 | 407.61% | 富國銀行 | $2 → $4 | 維護 | 等重 |
| 02/18/2021 | 788.32% | 派珀·桑德勒 | → $7 | 開始承保 | →超重 |
| 02/05/2021 | — | 摩根大通 | 升級 | 減重→中性 | |
| 05/18/2020 | 217.26% | B.萊利證券 | $3.5 → $2.5 | 維護 | 買 |
| 05/12/2020 | 26.9% | 富國銀行 | $1.5 → $1 | 維護 | 等重 |
| 03/04/2020 | 90.36% | 富國銀行 | $2.5 → $1.5 | 維護 | 等重 |
| 11/18/2019 | 344.16% | B.萊利證券 | → $3.5 | 恢復 | →購買 |
| 06/27/2019 | 280.71% | 奧本海默 | → $3 | 開始承保 | →跑贏大盤 |
| 01/04/2019 | 280.71% | B.萊利證券 | → $3 | 開始承保 | →購買 |
| 11/12/2018 | — | 富國銀行 | 評級下調 | 跑贏→市場表現 | |
| 11/12/2018 | — | 摩根大通 | 評級下調 | 中性→減持 | |
| 05/31/2018 | 407.61% | 環球海港 | → $4 | 開始承保 | →購買 |
What is the target price for Infinity Pharmaceuticals (INFI)?
無限制藥(INFI)的目標價是多少？
The latest price target for Infinity Pharmaceuticals (NASDAQ: INFI) was reported by B. Riley Securities on November 16, 2022. The analyst firm set a price target for $1.50 expecting INFI to rise to within 12 months (a possible 90.36% upside). 4 analyst firms have reported ratings in the last year.
B·萊利證券於2022年11月16日報道了無限制藥(納斯達克：INFI)的最新目標價。這家分析公司將目標價定為1.50美元，預計INFI將在12個月內升至(可能上行90.36%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Infinity Pharmaceuticals (INFI)?
分析師對無限制藥(Infinity PharmPharmticals)的最新評級是多少？
The latest analyst rating for Infinity Pharmaceuticals (NASDAQ: INFI) was provided by B. Riley Securities, and Infinity Pharmaceuticals downgraded their neutral rating.
分析師對無限制藥(納斯達克：INFI)的最新評級由B.萊利證券提供，無限制藥下調其中性評級。
When is the next analyst rating going to be posted or updated for Infinity Pharmaceuticals (INFI)?
Infinity PharmPharmticals(INFI)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Infinity Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Infinity Pharmaceuticals was filed on November 16, 2022 so you should expect the next rating to be made available sometime around November 16, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與Infinity製藥公司的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Infinity製藥的上一次評級是在2022年11月16日提交的，所以你應該預計下一次評級將在2023年11月16日左右的某個時候公佈。
Is the Analyst Rating Infinity Pharmaceuticals (INFI) correct?
分析師對無限制藥(INFI)的評級正確嗎？
While ratings are subjective and will change, the latest Infinity Pharmaceuticals (INFI) rating was a downgraded with a price target of $3.00 to $1.50. The current price Infinity Pharmaceuticals (INFI) is trading at is $0.79, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Infinity PharmPharmticals(INFI)評級為下調，目標價為3.00美元至1.50美元。Infinity製藥(INFI)目前的交易價格為0.79美元，超出了分析師的預測區間。
